RVTY Revvitydata gap · 84% coverage
Health Care · Health Care Equipment · close $152.64 (2026-10-16) · latest quarter in EDGAR: 2026-07-05
Revvity (RVTY) has a ThetaGrade House Rating of 35/100 (grade D), ranking #45 of 150 in Health Care. Its strongest pillars are cash flow (59) and profitability (48); its weakest is growth (22). Data gap: 3 factors without usable data, so 84% of the method weight is covered. TTM revenue growth is 4.1% and operating margin 12.3%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, 4Q gross-margin change. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 84% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 22| Revenue growth YoY (TTM) (13.3%) | 4.1% | 19 |
| EPS growth YoY (TTM) (13.3%) | -11.1% | 29 |
| Revenue acceleration (6.7%) | -5.7% | 16 |
Profitability
weight 18.5% (→20.0%) · 48| Operating margin (20.0%) | 12.3% | 48 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 34| Net debt / EBITDA (10.7%) | 2.86× | 29 |
| Current ratio (5.3%) | 1.80 | 38 |
| Interest coverage (4.0%) | 3.89× | 41 |
Cash flow
weight 12.33% (→13.3%) · 59| FCF margin (6.7%) | 17.8% | 66 |
| FCF yield (6.7%) | 3.0% | 52 |
Valuation
weight 12.33% (→13.3%) · 29| P/E (inverted) (6.7%) | 73.03× | 15 |
| EV/Sales (inverted) (6.7%) | 6.60× | 42 |
Technicals (EOD)
| RSI(14) | 59.3 |
| EMA 9 / 21 | 153.26 / 149.43 |
| 200-day SMA | 109.12 |
| Volume vs 20d avg | 0.63× |
| 20-day return | 4.0% |
Exit-rule monitor
- EXITRating break: House Rating below 60
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: DepreciationDepletionAndAmortization · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like RVTY's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is RVTY's House Rating?
- RVTY scores 35 out of 100 (grade D) as of 2026-10-16, ranking #45 of 150 Health Care stocks we cover.
- What do analysts say about RVTY?
- We do not have enough analyst-sentiment data to score this stock.
- When does RVTY report earnings next?
- We do not have a reliable estimate for RVTY's next earnings date (irregular SEC filing history); a rough window is 2026-08-03 to 2027-01-18. Check the company's investor-relations page.
- Is RVTY a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology